Immune status of thalassemic patients receiving deferiprone or combined deferiprone and desferrioxamine chelation treatment [2]

Acta Haematologica

Volumn 110, Issue 4, 2003, Pages 224-226

  Athanassiou Metaxa, M ^a   Tzimouli, V ^a   Economou, M ^a   Taparkou, A ^a   Tourkantoni, N ^a   Kanakoudi Tsakalidou, F ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTINUCLEAR ANTIBODY; BIOLOGICAL MARKER; CD4 ANTIGEN; CD8 ANTIGEN; DEFERIPRONE; DEFEROXAMINE; DNA ANTIBODY; DOUBLE STRANDED DNA; HEMOGLOBIN; HISTONE ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MICROSOME ANTIBODY; PROTEIN ANTIBODY; RETICULIN; SMOOTH MUSCLE ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BETA THALASSEMIA; BLOOD TRANSFUSION; CELLULAR IMMUNITY; CHELATION THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; HUMAN; HUMORAL IMMUNITY; IMMUNE FUNCTION TEST; IMMUNE RESPONSE; IMMUNE STATUS; IMMUNOPATHOLOGY; KIDNEY MICROSOME; LETTER; LIVER MICROSOME; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MONOTHERAPY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCHOOL CHILD; SIDE EFFECT; T LYMPHOCYTE; THALASSEMIA; THALASSEMIA MAJOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CHELATING AGENTS; CHILD; DEFEROXAMINE; HUMANS; IMMUNOPHENOTYPING; PYRIDONES;

EID: 0344737936     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074235     Document Type: Letter

References (12)

1. Pradhan V, Badakere S, Kanjaksha G: Antihistone and other autoantibodies in β-thalassemia major patients receiving iron chelators. Acta Hematol 2003;109:35-39.
2. Mehta J, Singhal S, Metha B: Oral chelator L1 and autoimmunity. Blood 1992;81:1970-1971.
3. Mehta J, Singhal S, Revenkar R, Walvalkar A, Chamlani A, Metha B: Fetal systemic lupus erythematosus in a patient taking oral chelator L1. Lancet 1991;337:298.
4. Berdoukas V, Bentley P, Frost H, Schnebli H: Toxicity of iron chelator L1. Lancet 1993;341: 1088.
5. Pattanapayasat K, Webster H, Togtawe P, Kongcharoen P, Hider R: Effect of orally active hydroxipiridone iron chelators on human lymphocyte function. Br J Haematol 1992;82:13-19.
6. Dwyer J, Wood C, McNamara J, Williams A, Andiman W, Rink I: Abnormalities in the immune system of children with beta-thalassemia major. Clin Exp Immunol;1987:68:621-629.
7. Grady R, Akbar A, De Sousa M, Giardina P, Hilgartner M: Transfusion-related immunologic abnormalities in beta-thalassemia major. Birth Defects 1987;23:587-593.
8. Speer C, Gahr M, Schuff-Werner P, Schroter W: Immunologic evaluation of children with homozygous β-thalassemia treated with desferrioxamine. Acta Haematol 1990;83:76-81.
9. Del Vecchio G, Schettini F, Piacente L, De Santis A, Giordano P, De Mattia D: Effects of deferiprone on immune status and cytokine pattern in thalassaemia major. Acta Haematol 2002;108:144-149.
10. Cohen A, Galanello R, Piga A, Di Palma A, Vullo C, Tricta F: Safety profile of the oral iron chelator deferiprone: A multicentre study. Br J Haematol 2000;108:305-312.
11. Loebstein R, Dalal I, Nibset-Brown E, Berkovitch M, Meydan N, Andrews D, Loubser M, Koren G, Roifman C, Olivieri N: Immune function in patients with beta-thalassemia receiving the orally active iron-chelating agent deferiprone. Br J Haematol 1997;98:597-600.
12. Lombardi G, Matera R, Minervini M, Cascavilla N, D'Arcangelo P, Carotenuto M, Di Giorgio G, Musto P: Serum levels of cytokines and soluble antigens in polytransfused patients with beta-thalassemia major: Relationship to immune status. Haematologica 1994;79:406-412.